Advertisement

Double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody could predict end-stage renal disease in ANCA-associated vasculitis: a monocentric pilot study

  • Byung-Woo Yoo
  • Sung Soo Ahn
  • Seung Min Jung
  • Jason Jungsik Song
  • Yong-Beom Park
  • Sang-Won LeeEmail author
Original Article

Abstract

Objectives

To investigate the detection rate of double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane (GBM) antibody at diagnosis and its clinical implication during follow-up in Korean patients with ANCA-associated vasculitis (AAV).

Methods

We retrospectively reviewed the medical records of 96 Korean AAV patients. We obtained data at diagnosis and assessed the poor outcomes of AAV such as all-cause mortality, relapse and end-stage renal disease (ESRD). Comparison of cumulative survivals were analysed by the Kaplan-Meier survival analysis, and hazard ratios (HRs) were obtained by the multivariable Cox hazard model.

Results

Seven of 96 AAV patients (7.3%) had double positivity for ANCA and anti-GBM. Among variables at diagnosis, there were no significant differences between patients with double positivity for ANCA and anti-GBM and those without. In the cumulative survival analysis, AAV patient with double positivity for ANCA and anti-GBM at diagnosis exhibited the lower cumulative ESRD-free survival rate than those without (P = 0.044) and furthermore, than those with positive for only ANCA and those with double negativity (P = 0.022). Myeloperoxidase (MPO)-ANCA, renal manifestation and five-factor score at diagnosis were also associated with ESRD occurrence in AAV patients. In the multivariable Cox hazards model using these 4 variables, only double positivity for ANCA and anti-GBM exhibited the significant association with ESRD occurrence during follow-up (HR 3.831).

Conclusions

Double positivity for ANCA and anti-GBM at diagnosis were observed in 7.3% of AAV patients, and it could predict ESRD occurrence during follow-up in Korean patients with AAV.

Key Points

7.3% of AAV patients had double positivity for ANCA and anti-GBM at diagnosis (total n = 96)

Double positivity for ANCA and anti-GBM could predict ESRD occurrence during follow-up (HR 9.021, P = 0.004)

AAV patients with double positivity for ANCA and anti-GBM exhibited the lower cumulative ESRD-free survival rate compared with those without (P = 0.044)

Keywords

Anti-glomerular basement membrane antibody Antineutrophil cytoplasmic antibody End-stage renal disease Vasculitis 

Notes

Author’s contribution

Sang-Won Lee and Byung-Woo Yoo contributed to the study conception and design. Sung Soo Ahn contributed to acquisition of material and data. Seung Min Jung and Sang-Won Lee contributed to the analysis and interpretation of data. The first draft of the manuscript was written by Byung-Woo Yoo, and all authors commented and revised on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding information

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2017R1D1A1B03029050) and a grant from the Korea Health Technology R and D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (HI14C1324).

Compliance with ethical standards

This study was approved by the institutional Review Board (IRB) of Severance Hospital (4-2017-0673), and the patient’s written informed consent was waived by the approving IRB, as this was a retrospective study.

Disclosures

None.

References

  1. 1.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11.  https://doi.org/10.1002/art.37715 CrossRefPubMedGoogle Scholar
  2. 2.
    Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66(2):222–227.  https://doi.org/10.1136/ard.2006.054593 CrossRefPubMedGoogle Scholar
  3. 3.
    McAdoo SP, Pusey CD (2017) Anti-glomerular basement membrane disease. Clin J Am Soc 12(7):1162–1172.  https://doi.org/10.2215/CJN.01380217 CrossRefGoogle Scholar
  4. 4.
    Hellmark T, Segelmark M (2014) Diagnosis and classification of Goodpasture’s disease (anti-GBM). J Autoimmun 48-49:108–112.  https://doi.org/10.1016/j.jaut.2014.01.024 CrossRefPubMedGoogle Scholar
  5. 5.
    Zhao J, Yang R, Cui Z, Chen M, Zhao MH, Wang HY (2007) Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies. Nephron Clin pract 107(2):c56–c62.  https://doi.org/10.1159/000107803 CrossRefPubMedGoogle Scholar
  6. 6.
    McAdoo SP, Tanna A, Hruskova Z, Holm L, Weiner M, Arulkumaran N, Kang A, Satrapova V, Levy J, Ohlsson S, Tesar V, Segelmark M, Pusey CD (2017) Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 92(3):693–702.  https://doi.org/10.1016/j.kint.2017.03.014 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW Jr et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33(8):1101–1107CrossRefGoogle Scholar
  8. 8.
    Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33(8):1094–1100CrossRefGoogle Scholar
  9. 9.
    Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68(12):1827–1832.  https://doi.org/10.1136/ard.2008.101279 CrossRefPubMedGoogle Scholar
  10. 10.
    Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune JW, St Clair EW, Luqmani RA (2001) A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44(4):912–920.  https://doi.org/10.1002/1529-0131(200104)44:4<912::aid-anr148>3.0.co;2-5 CrossRefPubMedGoogle Scholar
  11. 11.
    Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 90(1):19–27.  https://doi.org/10.1097/MD.0b013e318205a4c6 CrossRefPubMedGoogle Scholar
  12. 12.
    Csernok E, Moosig F (2014) Current and emerging techniques for ANCA detection in vasculitis. Nat Rev Rheumatol 10(8):494–501.  https://doi.org/10.1038/nrrheum.2014.78 CrossRefPubMedGoogle Scholar
  13. 13.
    Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suarez LF, Guillevin L, Hellmich B, Jayne D, Jennette JC, Kallenberg CGM, Moiseev S, Novikov P, Radice A, Savige JA, Sinico RA, Specks U, van Paassen P, Zhao MH, Rasmussen N, Damoiseaux J, Csernok E (2017) Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13(11):683–692.  https://doi.org/10.1038/nrrheum.2017.140 CrossRefPubMedGoogle Scholar
  14. 14.
    Mukhtyar C, Hellmich B, Jayne D, Flossmann O, Luqmani R (2006) Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Clin Exp Rheumatol 24(6 Suppl 43):S-93–S-98Google Scholar
  15. 15.
    Chen Y, Bao H, Liu Z, Liu X, Gao E, Zeng C, Zhang H, Liu Z, Hu W (2017) Risk factors for renal survival in Chinese patients with myeloperoxidase-ANCA-associated GN. Clin J Am Soc Nephrol 12(3):417–425.  https://doi.org/10.2215/cjn.06200616 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kristensen T, Gregersen JW, Krag SR, Ivarsen P (2016) The relation between histopathological classification and renal outcome, ANCA subtype and treatment regimens in ANCA-associated vasculitis. Clin Exp Rheumatol 34(3 Suppl 97):S105–S110PubMedGoogle Scholar
  17. 17.
    Park HJ, Jung SM, Song JJ, Park YB, Song JS, Lee SW (2019) Comparison of radiological and histological findings of lung parenchyma in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Yonsei Med J 60(5):454–460.  https://doi.org/10.3349/ymj.2019.60.5.454 CrossRefGoogle Scholar
  18. 18.
    Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T Hellmich B7, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75(9):1583–1594.  https://doi.org/10.1136/annrheumdis-2016-209133 CrossRefGoogle Scholar
  19. 19.
    Yoo J, Kim HJ, Ahn SS, Jung SM, Song JJ, Park YB, Lee SW (2017) Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis. Clin exp Rheumatol 35 Suppl 103(1):111–118PubMedGoogle Scholar
  20. 20.
    Olson SW, Arbogast CB, Baker TP, Owshalimpur D, Oliver DK, Abbott KC, Yuan CM (2011) Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 22(10):1946–1952.  https://doi.org/10.1681/asn.2010090928 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Li JN, Cui Z, Wang J, Hu SY, Jia XY, Guan Z, Chen M, Xie C, Zhao MH (2016) Autoantibodies against linear epitopes of myeloperoxidase in anti-glomerular basement membrane disease. Clin J Am Soc Nephrol 11(4):568–575.  https://doi.org/10.2215/cjn.05270515 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Gou SJ, Xu PC, Chen M, Zhao MH (2013) Epitope analysis of anti-myeloperoxidase antibodies in patients with ANCA-associated vasculitis. PLoS One 8(4):e60530.  https://doi.org/10.1371/journal.pone.0060530 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Srivastava A, Rao GK, Segal PE, Shah M, Geetha D (2013) Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody. Clin Rheumatol 32(9):1317–1322.  https://doi.org/10.1007/s10067-013-2268-5 CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  1. 1.Division of Rheumatology, Department of Internal MedicineYonsei University College of MedicineSeoulRepublic of Korea
  2. 2.Institute for Immunology and Immunological Diseases, Yonsei University College of MedicineSeoulRepublic of Korea

Personalised recommendations